US4523271090 - Common Stock - After market: 214 -0.03 (-0.01%)
NASDAQ:ILMN (1/27/2023, 7:14:56 PM)+1.25 (+0.59%)
GICS Sector | Health Care | ||
GICS Industry | Life Sciences Tools & Services |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 11-03 2022-11-03/amc | Earnings (Next) | 02-08 2023-02-08 |
Ins Owners | 0.15% | Inst Owners | 186.53% |
Market Cap | 33.67B | Shares | 157.30M |
PE | 78.4 | Fwd PE | 68.61 |
Dividend Yield | N/A | Analysts | 71.2 |
IPO | 06-28 2000-06-28 |
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 9,800 full-time employees. The company went IPO on 2000-06-28. The firm operates through two segments: Core Illumina and GRAIL. Core Illumina products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. GRAIL is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Customers use its platforms to perform whole genome, de novo, exome and ribonucleic acid (RNA) sequencing, and targeted resequencing of specific gene regions and genes. The firm's BeadArray technology produces arrays that can perform many assays simultaneously. Customers use its array-based genotyping consumables for a range of analyses, including diverse species, disease-related mutations, and genetic characteristics associated with cancer.
ILLUMINA INC
5200 Illumina Way
San Diego CALIFORNIA 92122
P: 18582024500.0
CEO: Francis A. deSouza
Employees: 9800
Website: https://www.illumina.com
Argus has downgraded Illumina (ILMN) to hold from buy citing falling margins and worsening outlook.
Outlays from the National Institutes of Health ((NIH)) for December 2022 decreased ~4% Y/Y (-35% versus November 2022), according to report from Baird Equity Research.December 2022...
Sharp Tesla price cuts and some notable earnings were in focus.
Here you can normally see the latest stock twits on ILMN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: